IMAGE 1 (Immune Modulation and Gemcitabine Evaluation), a Randomised, Open-label Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer | British Journal of Cancer (nature.com)

Dalgleish, A., Stebbing, J., Adamson, D. et al. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer 115, 789–796 (2016). https://doi.org/10.1038/bjc.2016.271